Pharmaceutical distribution business ranking third in the industry. In 1H25, the company's distribution revenue reached Rmb110bn, ranking third in the industry following Sinopharm Group (01099.HK, N-R) and Shanghai Pharmaceuticals (02607.HK, BUY). 1) Distribution: The company continues to expand its innovative drug portfolio, with its business model gradually transitioning from traditional distribution to a dual-wheel drive of distribution and in-depth marketing. In 1H25, the revenue of the drug distributio ...

Group 1 - TopBuild Corp. has a positive revenue outlook, benefiting from both cyclical and secular drivers [1] - The reversal in the interest rate cycle is expected to unlock growth opportunities for the company [1] Group 2 - The company is positioned to capitalize on medium-term investment strategies that focus on catalysts for value unlocking [1]

Remember, big tech did clean M&As for years.So what changed?It was the Biden-era regulatory assault.The most recognizable face was Lina Khan at FTC.Though to be fair, it's now an international affair.And it's also been continued by the current admin.Because Trump 2 is pro-crypto, but anti-Big Tech.And you know what? I get it.Big Tech did back wokes and censor citizens.But big M&As aren't really big wins for bigcos.They're more like surrenders.They signify that big tech couldn't build, so had to buy.And each ...